PS 25. Construction of translational medicine platform of urinary tract cancer
Plenary Session

PS 25. Construction of translational medicine platform of urinary tract cancer

Yong Xu

Department of Urology, Tianjin University Hospital, Tianjin, China

Translational medicine is a new medical model focusing on overcoming the serious imbalance among the basic research, its clinical and public health application. Its core is to establish effective ties among basic medical researchers, public health workers and doctors who know the needs of patients, particularly translating the molecular medical research results to suitable disease prevention, diagnosis, treatment and prevention methods effectively. Translational Medicine, personalized medicine, and predictable medicine constitute the systematic medicine consist of system pathology, pharmacology, comprehensive diagnosis and treatment system. It is new modern medicine based on genome genetics, genomics chip technology and systems biology.

Tumor is a kind of disorders caused by uncontrolled proliferating cell which originated from multiple levels of genetic and epigenetic abnormalities. The genetic (epigenetic) of cancer cell is highly unstable, extremely heterogeneous and strongly environmentally adaptable. These make tumor difficult disease lacking of diagnosis and treatment methods and the leading cause of death. Although each state has invested a lot of money, manpower and material resources to try to improve the survival of cancer patients, but results are not satisfactory. Apart from getting a flood of research papers, the benefit of cancer patients get is very limited. With rapid development of genome sequencing technology, nano and information science, comprehensive and profound understanding of the biological behavior of tumor shall get greatly accelerated. Thus, it has become a consensus of cancer researchers that it is necessary constructing translational medical research platform to make the conversion between basic research results and clinical application faster than before, and enhancing the survival of cancer patients.

Urinary system tumors do not occupy the most important position in cancer incidence in China, but they are the most common diseases among urology disorders. Their morbidity and mortality are increasing. Tumor can occur in various parts of genitourinary system, the most common is bladder cancer, followed by kidney tumor. In American and European countries the most common urologic tumor is prostate cancer. Over the past decade, with the social and economic development and improvement of people's living standards, in some developed cities and towns in China prostate cancer incidence has become significantly higher. Even in a few cities prostate cancer has replaced bladder carcinoma, being the most important male cancer. Thus, it is of great significance to solute the problem of genitourinary cancer, which is also the most important purpose of constructing Tianjin platform of translational research in genitourinary into the purpose of medical research platform.

Construction of Tianjin platform of translational research in urinary oncology will help to promote the clinical transformation of existing scientific and technological achievements. It is conducive to improving the ties between basic research projects and clinical needs. And it will be useful to carry out the scientific and objective evaluation of implementation of those applied results, new techniques and treatment methods. This will form interactive and comprehensive relations between basic research and clinical applications, and promote the diagnosis and treatment of urinary cancer to a higher level. In the process of construction of the platform, the following aspects will be included: (I) Establishment of the administration department, including Committee of Experts, management office and outreach coordination office; (II) Establishment of bases where basic research project can be implemented, as follows: pathological information and quality control management system, basic and clinical research laboratory, biological immunotherapy research lab, cancer stem cells research lab, and post-genome research lab; (III) Construction of translation and application centers, including: surgical operation simulation and new technique conversion lab, research and development platform of new drug, and personalized treatment research lab; (IV) Establishment of translational medicine service centers, including: Translational medicine information platform, sample banks, statistics and follow-up office, imaging and bioinformatics workstations and animal laboratory.

Immediate objectives: (I) On the basis of Tianjin collaborative group of prostate cancer, Professional Committee of Urinary Oncology under Chinese Anti-Cancer Association, Tianjin Institute of Urology where the chairman of Tianjin Urology Committee is, the project will integrate the basic research and clinical resources of the urinary oncology in Tianjin and establish collaboration pattern of multi-disciplinary joint research around the city. (II) Realization of the clinical application of recombinant BCG and personalized DC-peptide vaccine in chemotherapy and immunotherapy of urinary cancer. (III) Establishment of the early warning system composed of biomarkers of molecular pathology. (IV) Realization of the mature clinical application of diagnostic and classification systems composed of products of gene chip with biomarkers. (V) On the basis of translational research platforms, Carrying out further research on the pathogenesis, related systematic research projects of urinary oncology, new clinical treatment methods, and the timely transformation of the research results to clinical application. (VI) With the translational medicine platform running well, introducing leading talent including "Yangtze River Scholar" at home and abroad to promote and facilitate international cooperation, making the national key discipline of urology a world-class subject.

DOI: 10.3978/j.issn.2223-4683.2012.s263

Article Options

Download Citation